January 28 – 30, 2025 | Boston, MA

The 8th Annual DDR Inhibitors Summit in Boston this January will bring together top organizations and many more to collaborate, share insights, and shape the future of DDR therapeutics for cancer treatment.

Large pharma like Novartis, AstraZeneca, and Merck are driving the next wave of DDR inhibitor innovation with precision biomarker strategies, cutting-edge ATR and WEE1 inhibitor combinations, and next-gen PARP inhibitors. Meanwhile, emerging biotech leaders, including IDEAYA and ForX Therapeutics, are advancing the field with AI-driven platforms and genetic screening to uncover new targets and develop selective inhibitors.

Beacon’s DDR Lead Research Analyst, Dasha Kaloujskaia, will join the expert speaker faculty to deliver “A Comprehensive Overview of DDR Therapies: Key Insights & Combination Strategies. ” We will review the DDR landscape as of 2024, share a case study on PARP combinations in key indications, and discuss emerging trends to watch for in 2025. This session begins at 4:00 p.m. on Day One and you can discover further details here.